| Market Cap | 26.53M | P/E | - | EPS this Y | 38.80% | Ern Qtrly Grth | - |
| Income | -39.7M | Forward P/E | -0.69 | EPS next Y | -7.30% | 50D Avg Chg | -45.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -34.00% |
| Dividend | N/A | Price/Book | 0.77 | EPS next 5Y | - | 52W High Chg | -81.00% |
| Recommedations | 1.60 | Quick Ratio | 40.12 | Shares Outstanding | 59.11M | 52W Low Chg | 51.00% |
| Insider Own | 0.24% | ROA | -22.06% | Shares Float | 41.05M | Beta | 1.27 |
| Inst Own | 104.58% | ROE | -51.87% | Shares Shorted/Prior | 6.26M/6.40M | Price | 1.09 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 1,770,519 | Target Price | 8.00 |
| Oper. Margin | - | Earnings Date | Aug 6 | Volume | 342,146 | Change | -7.63% |
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| venBio Global Strategic Fund I... | 10% Owner 10% Owner | May 25 | Sell | 4.1236 | 702,737 | 2,897,806 | 1,905,430 | 05/27/22 |